Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Executive Summary
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.